JP2014503590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503590A5 JP2014503590A5 JP2013551323A JP2013551323A JP2014503590A5 JP 2014503590 A5 JP2014503590 A5 JP 2014503590A5 JP 2013551323 A JP2013551323 A JP 2013551323A JP 2013551323 A JP2013551323 A JP 2013551323A JP 2014503590 A5 JP2014503590 A5 JP 2014503590A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- pharmaceutically acceptable
- independently selected
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- -1 hydroxy, methylamino Chemical group 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000005879 dioxolanyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- GCNXSBXFNLSWIY-UHFFFAOYSA-N 2-methoxy-4-[[4-(methylamino)-7-(2,4,6-trifluorophenyl)-6,7-dihydro-5h-cyclopenta[d]pyrimidin-2-yl]amino]benzonitrile Chemical compound N=1C=2C(C=3C(=CC(F)=CC=3F)F)CCC=2C(NC)=NC=1NC1=CC=C(C#N)C(OC)=C1 GCNXSBXFNLSWIY-UHFFFAOYSA-N 0.000 claims 1
- NJFIOBFAEKDSAX-UHFFFAOYSA-N 2-methoxy-4-[[7-(2-methoxyphenyl)-4-(methylamino)-6,7-dihydro-5h-cyclopenta[d]pyrimidin-2-yl]amino]benzonitrile Chemical compound N=1C=2C(C=3C(=CC=CC=3)OC)CCC=2C(NC)=NC=1NC1=CC=C(C#N)C(OC)=C1 NJFIOBFAEKDSAX-UHFFFAOYSA-N 0.000 claims 1
- HVNJAMMYDKMJBD-UHFFFAOYSA-N 2-methoxy-4-[[7-(3-methoxyphenyl)-4-(methylamino)-6,7-dihydro-5h-cyclopenta[d]pyrimidin-2-yl]amino]benzonitrile Chemical compound N=1C=2C(C=3C=C(OC)C=CC=3)CCC=2C(NC)=NC=1NC1=CC=C(C#N)C(OC)=C1 HVNJAMMYDKMJBD-UHFFFAOYSA-N 0.000 claims 1
- FSTPMFASNVISBU-UHFFFAOYSA-N 2-methoxybenzonitrile Chemical compound COC1=CC=CC=C1C#N FSTPMFASNVISBU-UHFFFAOYSA-N 0.000 claims 1
- UGGXLWNCOJEQSE-UHFFFAOYSA-N 4-[[7-(2-chlorophenyl)-4-(methylamino)-6,7-dihydro-5h-cyclopenta[d]pyrimidin-2-yl]amino]-2-methoxybenzonitrile Chemical compound N=1C=2C(C=3C(=CC=CC=3)Cl)CCC=2C(NC)=NC=1NC1=CC=C(C#N)C(OC)=C1 UGGXLWNCOJEQSE-UHFFFAOYSA-N 0.000 claims 1
- QPKWNINCETVTTE-UHFFFAOYSA-N 4-[[7-(2-fluorophenyl)-4-(methylamino)-6,7-dihydro-5h-cyclopenta[d]pyrimidin-2-yl]amino]-2-methoxybenzonitrile Chemical compound N=1C=2C(C=3C(=CC=CC=3)F)CCC=2C(NC)=NC=1NC1=CC=C(C#N)C(OC)=C1 QPKWNINCETVTTE-UHFFFAOYSA-N 0.000 claims 1
- HPEAAAQYIBAHCB-UHFFFAOYSA-N 4-[[7-(4-chloro-2-fluorophenyl)-4-(methylamino)-6,7-dihydro-5h-cyclopenta[d]pyrimidin-2-yl]amino]-2-methoxybenzonitrile Chemical compound N=1C=2C(C=3C(=CC(Cl)=CC=3)F)CCC=2C(NC)=NC=1NC1=CC=C(C#N)C(OC)=C1 HPEAAAQYIBAHCB-UHFFFAOYSA-N 0.000 claims 1
- YHEMFEUAFNYLBN-UHFFFAOYSA-N 4-[[7-(4-fluorophenyl)-7-methyl-4-(methylamino)-5,6-dihydrocyclopenta[d]pyrimidin-2-yl]amino]-2-methoxybenzonitrile Chemical compound N=1C(C(CC2)(C)C=3C=CC(F)=CC=3)=C2C(NC)=NC=1NC1=CC=C(C#N)C(OC)=C1 YHEMFEUAFNYLBN-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000002560 nitrile group Chemical group 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437279P | 2011-01-28 | 2011-01-28 | |
| US61/437,279 | 2011-01-28 | ||
| PCT/US2012/022665 WO2012103297A1 (en) | 2011-01-28 | 2012-01-26 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503590A JP2014503590A (ja) | 2014-02-13 |
| JP2014503590A5 true JP2014503590A5 (enExample) | 2015-02-26 |
| JP5908499B2 JP5908499B2 (ja) | 2016-04-26 |
Family
ID=45688981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551323A Expired - Fee Related JP5908499B2 (ja) | 2011-01-28 | 2012-01-26 | β−アミロイド産生を減少させるための化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8710061B2 (enExample) |
| EP (1) | EP2668168B1 (enExample) |
| JP (1) | JP5908499B2 (enExample) |
| KR (1) | KR20140014152A (enExample) |
| CN (1) | CN103328451B (enExample) |
| AR (1) | AR084944A1 (enExample) |
| AU (1) | AU2012211301B2 (enExample) |
| BR (1) | BR112013018298A2 (enExample) |
| CA (1) | CA2825906A1 (enExample) |
| EA (1) | EA201391097A1 (enExample) |
| IL (1) | IL226677A (enExample) |
| MX (1) | MX2013008699A (enExample) |
| SG (1) | SG191840A1 (enExample) |
| TW (1) | TW201309655A (enExample) |
| WO (1) | WO2012103297A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX374634B (es) | 2013-04-15 | 2025-03-06 | Fmc Corp Star | Amidas fungicidas. |
| WO2016080516A1 (ja) * | 2014-11-21 | 2016-05-26 | 味の素株式会社 | Ｄｒｐ１重合阻害剤 |
| EP3778605A3 (en) * | 2015-02-13 | 2021-03-10 | Dana Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
| CN105017046A (zh) * | 2015-07-15 | 2015-11-04 | 上海博康精细化工有限公司 | 一种4-环丙胺基丁酸乙酯的制备方法 |
| WO2017012559A1 (zh) * | 2015-07-21 | 2017-01-26 | 广州再极医药科技有限公司 | 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| WO2019101984A1 (en) * | 2017-11-27 | 2019-05-31 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives |
| EP3919484B1 (en) * | 2019-01-29 | 2023-05-24 | Shandong Xuanzhu Pharma Co., Ltd. | Hexone glucokinase inhibitor and use thereof |
| CN112028839B (zh) * | 2020-09-30 | 2022-04-12 | 中国海洋大学 | 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1698627A1 (en) | 2000-09-15 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminoquinazoline DERIVATIVE |
| TW201030002A (en) * | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| US8637525B2 (en) * | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (zh) * | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
-
2012
- 2012-01-17 TW TW101101816A patent/TW201309655A/zh unknown
- 2012-01-26 KR KR1020137022590A patent/KR20140014152A/ko not_active Withdrawn
- 2012-01-26 JP JP2013551323A patent/JP5908499B2/ja not_active Expired - Fee Related
- 2012-01-26 EP EP12704954.2A patent/EP2668168B1/en not_active Not-in-force
- 2012-01-26 CA CA2825906A patent/CA2825906A1/en not_active Abandoned
- 2012-01-26 EA EA201391097A patent/EA201391097A1/ru unknown
- 2012-01-26 AU AU2012211301A patent/AU2012211301B2/en not_active Ceased
- 2012-01-26 CN CN201280006419.7A patent/CN103328451B/zh not_active Expired - Fee Related
- 2012-01-26 US US13/358,822 patent/US8710061B2/en active Active
- 2012-01-26 BR BR112013018298A patent/BR112013018298A2/pt not_active IP Right Cessation
- 2012-01-26 MX MX2013008699A patent/MX2013008699A/es unknown
- 2012-01-26 WO PCT/US2012/022665 patent/WO2012103297A1/en not_active Ceased
- 2012-01-26 SG SG2013051552A patent/SG191840A1/en unknown
- 2012-01-27 AR ARP120100283A patent/AR084944A1/es not_active Application Discontinuation
-
2013
- 2013-05-30 IL IL226677A patent/IL226677A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503590A5 (enExample) | ||
| JP2012515205A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2015503507A5 (enExample) | ||
| JP2009532464A5 (enExample) | ||
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| JP2017532360A5 (enExample) | ||
| JP5710251B2 (ja) | 新規ヘテロ環化合物およびその使用 | |
| PE20121511A1 (es) | Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa | |
| JP2011500758A5 (enExample) | ||
| JP2015506382A5 (enExample) | ||
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| JP2014513139A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| RU2015135891A (ru) | Новые производные пиразола | |
| JP2013509392A5 (enExample) | ||
| JO3377B1 (ar) | مشتقات بيريدينيل وبيريدينيل مندمج | |
| EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
| JP2009515949A5 (enExample) | ||
| AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
| RU2017140446A (ru) | Гетероарильное производное или его фармацевтически приемлемая соль, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с pi3 киназами, содержащая данное действующее вещество | |
| JP2018522852A5 (enExample) | ||
| JP2016507551A5 (enExample) | ||
| JP2016523907A (ja) | 置換されたテトラヒドロカルバゾールおよびカルバゾールカルボキサミド化合物 |